Advertisement

PharmacoEconomics & Outcomes News

, Volume 832, Issue 1, pp 24–24 | Cite as

Pembrolizumab and atezolizumab cost effective in metastatic NSCLC

Clinical study
  • 5 Downloads

Reference

  1. Giuliani J, et al. Financial Toxicity and Non-small Cell Lung Cancer Treatment: The Optimization in the Choice of Immune Check Point Inhibitors. Anticancer Research 39: 3961-3965, No. 7, Jul 2019. Available from: URL: http://doi.org/10.21873/anticanres.13550

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations